Smits, Mark M.

Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment

Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesRenal Diseases and Glomerulopathies

Cited by 887

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 407

Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial

van Beers, C. A. J., DeVries, J. H., Kleijer, S. J., Smits, M. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Diamant, M., Snoek, F. J., & Serné, E. H. (2016) · The Lancet Diabetes & Endocrinology

Diabetes Management and ResearchDiabetes Management and Education

Cited by 386

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

van Bommel, E. J. M., Muskiet, M. H. A., van Baar, M. J. B., Tonneijck, L., Smits, M. M., Emanuel, A. L., Bozovic, A., Danser, A. H. J., Geurts, F., Hoorn, E. J., et al. (2020) · Kidney International

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 363

Safety of Semaglutide

Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 332

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pouwels, P. J. W., Pieters-van den Bos, I. C., Hoekstra, T., Diamant, M., van Raalte, D. H., & Cahen, D. L. (2016) · Diabetologia

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 142

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetologia

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 126

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., ter Wee, P. M., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 113

Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes

Heuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research

Diabetes Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 106

Acute renal haemodynamic effects of glucagon‐like peptide‐1 receptor agonist exenatide in healthy overweight men

Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 102

Gastrointestinal actions of glucagon‐like peptide‐1‐based therapies: glycaemic control beyond the pancreas

Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 74

Postprandial renal haemodynamic effect of lixisenatide vs once‐daily insulin‐glulisine in patients with type 2 diabetes on insulin‐glargine: An 8‐week, randomised, open‐label trial

Tonneijck, L., Muskiet, M. H. A., Smits, M. M., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 62

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males

Smits, M. M., Muskiet, M. H. A., Tonneijck, L., Hoekstra, T., Kramer, M. H. H., Diamant, M., & van Raalte, D. H. (2016) · British Journal of Clinical Pharmacology

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 60

Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus

Tonneijck, L., Muskiet, M. H. A., Blijdorp, C. J., Smits, M. M., Twisk, J. W., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., Hoorn, E. J., et al. (2019) · American Journal of Physiology-Renal Physiology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 57

Biliary effects of liraglutide and sitagliptin, a 12‐week randomized placebo‐controlled trial in type 2 diabetes patients

Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Diamant, M., Nieuwdorp, M., Groen, A. K., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementGallbladder and Bile Duct Disorders

Cited by 56

Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial

Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Diamant, M., & van Raalte, D. H. (2017) · European Journal of Endocrinology

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 54

Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database

Pizzimenti, V., Giandalia, A., Cucinotta, D., Russo, G. T., Smits, M., Cutroneo, P. M., & Trifirò, G. (2016) · Journal of Clinical Pharmacy and Therapeutics

Pharmacovigilance and Adverse Drug ReactionsGallbladder and Bile Duct Disorders

Cited by 30

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial

Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pieters-van den Bos, I. C., Vendrik, K. E. W., Hoekstra, T., Bruno, M. J., Diamant, M., van Raalte, D. H., et al. (2017) · Diabetes Care

Diabetes Treatment and ManagementPancreatitis Pathology and Treatment

Cited by 23

Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes

Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Diamant, M., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2017) · Diabetic Medicine

Diabetes Treatment and ManagementPancreatitis Pathology and Treatment

Cited by 7